Please upgrade your browser.
Tumours with an immunopositivity for serotonin had a longer RCCspecific survival and tumours with an immunopositivity for CD56 and NSE had a shorter RCCspecific survival but the difference was not significant.
Pfizer Oncology (NYSE: PFE) will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets.
Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis - Abstract
Department of Urology, University of Munich, Klinikum Grosshadern, Marchioninistr. 15, 81377, Munchen, Germany.
Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
Renal oncocytoma: a comparative clinicopathologic study and fluorescent in-situ hybridization analysis of 73 cases with long-term follow-up
Clinical studies have confirmed that renal oncocytoma (RO) is a benign neoplasm with excellent prognosis. In diagnostically challenging cases of renal oncocytic epithelial neoplasms, fluorescent in-situ hybridization (FISH) is increasingly being used and its ability to distinguish RO from chromophobe renal cell carcinoma (ChRCC) has been documented.
The diagnosis of kidney cancerrenal cell carcinomawas shocking, Creel says.
Leptomeningeal Carcinomatosis From Renal Cell Cancer: Treatment Attempt With Radiation And Sunitinib
The authors describe the case of leptomeningeal carcinomatosis in a 72-year-old male with known brain and lung metastases from renal cell cancer without previous systemic therapy.
After Todd Lappin was diagnosed with cancer he would tell people that the kidney doctors removed was never his favorite kidney.
We are pleased to have the opportunity to present additional analyses from our Phase 2 clinical trial of tivozanib in patients with renal cell cancer, as well as data from a Phase 1 clinical trial of AV-299 in collaboration with Merck . . .
Morphology, Attenuation, Size, and Structure (MASS) Criteria: Assessing Response and Predicting Clinical Outcome in Metastatic Renal Cell Carcinoma on Antiangiogenic Targeted Therapy
The objective of our study was to evaluate response assessment and predict clinical outcome in patients with metastatic renal cell carcinoma (RCC) receiving antiangiogenic targeted therapy. Target lesions were assessed on routine contrast-enhanced CT (CECT) images obtained during the portal venous phase using new response criteria.
|NeonCRM by Neon One|